Nihon Kohden (OTCMKTS:NHNKY) Lowered to “Hold” Rating by UBS Group

UBS Group downgraded shares of Nihon Kohden (OTCMKTS:NHNKY) from a strong-buy rating to a hold rating in a research report sent to investors on Wednesday morning,Zacks.com reports.

Separately, Zacks Research upgraded shares of Nihon Kohden to a “hold” rating in a research report on Monday, April 27th. Two investment analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the stock has a consensus rating of “Hold”.

Nihon Kohden Trading Down 2.8%

Shares of OTCMKTS NHNKY opened at $9.23 on Wednesday. Nihon Kohden has a 1 year low of $8.12 and a 1 year high of $14.21. The firm’s 50-day moving average is $9.17 and its 200-day moving average is $9.68. The firm has a market capitalization of $1.55 billion, a PE ratio of 16.77 and a beta of 0.37.

Nihon Kohden (OTCMKTS:NHNKY) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.09). Nihon Kohden had a return on equity of 9.08% and a net margin of 5.90%.The business had revenue of $297.47 million for the quarter, compared to the consensus estimate of $299.98 million. As a group, equities research analysts anticipate that Nihon Kohden will post 0.6 earnings per share for the current fiscal year.

About Nihon Kohden

Nihon Kohden Corporation is a Tokyo-based manufacturer of medical electronic equipment, founded in 1951. The company has built a reputation for innovation in patient monitoring and diagnostic systems, developing one of Japan’s earliest electrocardiogram (ECG) machines and pioneering transistor-based oscilloscopes for clinical use. Over the decades, Nihon Kohden has expanded its product portfolio to address a wide range of healthcare needs, from emergency response to intensive care and neurology.

The company’s core offerings include patient monitors, ECG and electroencephalograph (EEG) devices, defibrillators, infusion pumps, and neuromonitoring systems.